Apollon Formularies plc Notice of AGM (3413I)

TIDMAPOL

RNS Number : 3413I

Apollon Formularies plc

02 December 2022

2 December 2022

Apollon Formularies Plc

Notice of AGM

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), announces that notice of its Annual General Meeting ('AGM') has been posted to shareholders, and will shortly be available at the Company website on https://www.apollon.org.uk/ . The AGM will be held on 30 December 2022 at 10am, at 48 Warwick Street, London, W1B 5AW.

The directors of the Company accept responsibility for the contents of this announcement.

ENDS

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies

   Tel:                                         +44 771 198 0221 
   Stene Jacobs                        stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)

   Tel:                                         +44 207 220 9795 
   Guy Miller                             gm@peterhousecapital.com

Blytheweigh (Financial PR/IR-London)

   Tel:                                         +44 207 138 3204 
   Tim Blythe/Megan Ray       apollon@blytheray.com

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFFDFELLIIF

(END) Dow Jones Newswires

December 02, 2022 02:00 ET (07:00 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2024 to Apr 2024